Russell Skibsted - 24 Jul 2025 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Financial Officer
Signature: /s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 24 Jul 2025
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 18 Sep 2025, 16:23:32 UTC
Date Of Original Report: 28 Jul 2025
Previous filing: 18 Jul 2024
Next filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SKIBSTED RUSSELL	Chief Financial Officer	C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	18 Sep 2025	0001308105

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PCSA	Restricted Stock Units						28,000	24 Jul 2025	Common Stock	28,000	$0.000000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of 50% on 7/16/25 and the remainder upon achievement of certain criteria.

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.